Valeant Pharmaceuticals International, Inc., issued the following comments in response to inquiries from investors regarding Deb Jorn’s departure from Valeant.
It is our understanding that Deb Jorn decided to leave Valeant for personal reasons. Her departure is not the result of an action taken by the Ad Hoc Committee of the Board of Directors.
“Deb is a true talent who consistently operated at the highest levels of performance and did an outstanding job as the driving force behind the successful launches of Jublia® and Luzu®,” commented J. Michael Pearson, chief executive officer. “While we will miss Deb greatly, we are confident that the Dermatology and Gastrointestinal businesses will continue to deliver strong operating performance under the leadership of Dr. Ari Kellen.”
On March 2, 2016, Valeant confirmed that Deb Jorn resigned as Executive Vice President and Company Group Chairman, effective immediately. In this role, she was responsible for running the company’s U.S. Dermatology and Gastrointestinal businesses. Eric Abramson, Vice President Dermatology & Immunology Marketing, has been appointed General Manager of the U.S. Dermatology business and Dr. Ari Kellen, Executive Vice President and Company Group Chairman will oversee Valeant’s gastrointestinal business.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
